Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: A French multicentre observational study

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Baffert, Sandrine ^a   Cottu, Paul ^a   Kirova, Youlia M ^a   Mercier, Florence ^b   Simondi, Cécile ^a   Bachelot, Thomas ^c   Le Rhun, Emilie ^d   Levy, Christelle ^e   Gutierrez, Maya ^a   Madranges, Nicolas ^f   Moldovan, Cristian ^g   Coudert, Bruno ^h   Spaëth, Dominique ⁱ   Serin, Daniel ^j   Cotté, François Emery ^k   Benjamin, Laure ^k   Maillard, Cathie ^l   Laulhere Vigneau, Sabine ^l   Durand Zaleski, Isabelle ^m  

^a INSTITUT CURIE   (France)

^b STAT PROCESS   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f INSTITUT BERGONIÉ   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h Ctr Anti Cancereux   (France)

ⁱ Centre d'Oncologie de Gentilly   (France)

^j INSTITUT SAINTE CATHERINE   (France)

^k GLAXOSMITHKLINE   (France)

^l Ceri Medical   (France)

^m HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Brain metastases; Breast cancer; Cerb 2; Costs and cost analysis; Health care costs; HER2 positive; Treatment pattern

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; ECONOMICS; FEMALE; FRANCE; GENETICS; HEALTH CARE COST; HUMAN; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOLOGY; PROTO ONCOGENE; RETROSPECTIVE STUDY; STATISTICS; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FRANCE; GENES, ERBB-2; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84886735120     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-456     Document Type: Article

References (29)

1. Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival. Dabakuyo TS, Bonnetain F, Roignot P, Poillot ML, Chaplain G, Altwegg T, Hedelin G, Arveux P, Ann Oncol 2008 19 2 276 283 10.1093/annonc/mdm491 17962200 (Pubitemid 351201708)
2. Brain metastasis-evidence based management. Biswas G, Bhagwat R, Khurana R, Menon H, Prasad N, Parikh PM, J Cancer Res Ther 2006 2 1 5 13 10.4103/0973-1482.19768 17998665
3. Brain metastases: the HER2 paradigm. Lin NU, Winer EP, Clin Cancer Res 2007 13 6 1648 1655 10.1158/1078-0432.CCR-06-2478 17363517 (Pubitemid 46952930)
4. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R, Cancer 2006 107 4 696 704 10.1002/cncr.22041 16826579 (Pubitemid 44232661)
5. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, et al. Clin Cancer Res 2011 17 14 4834 4843 10.1158/1078-0432.CCR-10-2962 21768129
6. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients. Cutuli B, Cottu PH, Guastalla JP, Mechin H, Costa A, Jourdan R, Breast Cancer Res Treat 2006 95 1 55 64 10.1007/s10549-005-9034-6 16261401 (Pubitemid 43228081)
7. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Nunes RA, Harris LN, Clin Breast Cancer 2002 3 2 125 135 discussion 136-127 10.3816/CBC.2002.n.017 12123536
8. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Niwinska A, Murawska M, Pogoda K, Ann Oncol 2010 21 5 942 948 10.1093/annonc/mdp407 19840953
9. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, et al. J Clin Oncol 2005 23 19 4265 4274 10.1200/JCO.2005.04.173 15911866 (Pubitemid 46207001)
10. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. N Engl J Med 2001 344 11 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
11. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S, Oncologist 2010 15 2 122 129 10.1634/theoncologist.2009-0240 20156908
12. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, et al. J Clin Oncol 2008 26 34 5544 5552 10.1200/JCO.2008.16.2578 18955454
13. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y, Cancer 2010 116 2 302 308 10.1002/cncr.24735 19937674
14. Brain metastases from breast cancer: management approach. Wadasadawala T, Gupta S, Bagul V, Patil N, J Cancer Res Ther 2007 3 3 157 165 10.4103/0973-1482.37409 18079579 (Pubitemid 350293673)
15. Metastatic breast cancer: we do need primary cost data. Bonastre J, Jan P, Barthe Y, Koscielny S, Breast 2012 21 3 384 388 10.1016/j.breast.2012.03.012 22520336
16. Health care costs for treatment of disseminated breast cancer. Dahlberg L, Lundkvist J, Lindman H, Eur J Cancer 2009 45 11 1987 1991 10.1016/j.ejca.2009.03.023 19398326
17. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Foster TS, Miller JD, Boye ME, Blieden MB, Gidwani R, Russell MW, Cancer Treat Rev 2011 37 6 405 415 21477928
18. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. Arch Pathol Lab Med 2007 131 1 18 43 19548375 (Pubitemid 46174133)
19. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W, Int J Radiat Oncol Biol Phys 2008 70 2 510 514 10.1016/j.ijrobp.2007.06.074 17931798
20. Validation of the graded prognostic assessment index for patients with brain metastases. Nieder C, Marienhagen K, Geinitz H, Molls M, Acta Oncol 2009 48 3 457 459 10.1080/02841860802342390 18781455
21. A validation study of a new prognostic index for patients with brain metastases: the graded prognostic assessment. Sperduto CM, Watanabe Y, Mullan J, Hood T, Dyste G, Watts C, Bender GP, Sperduto P, J Neurosurg 2008 109 Suppl 87 89 19123893
22. Median regression with censored cost data. Bang H, Tsiatis AA, Biometrics 2002 58 3 643 649 10.1111/j.0006-341X.2002.00643.x 12229999 (Pubitemid 35001482)
23. Some insight on censored cost estimators. Zhao H, Cheng Y, Bang H, Stat Med 2011 30 19 2381 2388 10.1002/sim.4295 21748774
24. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, et al. Br J Cancer 2012 106 1 25 31 10.1038/bjc.2011.531 22127284
25. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer. Perez-Ellis C, Goncalves A, Jacquemier J, Marty M, Girre V, Roche H, Brain E, Moatti JP, Viens P, Le Corroller-Soriano AG, Am J Clin Oncol 2009 32 5 492 498 10.1097/COC. 0b013e3181931277 19487912
26. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab. Poncet B, Colin C, Bachelot T, Jaisson-Hot I, Derain L, Magaud L, Fournel-Federico C, Mousseau M, Tigaud JD, Jacquin JP, et al. Am J Clin Oncol 2009 32 4 369 374 10.1097/COC.0b013e31818c08d3 19381078
27. Burden of breast cancer with brain metastasis: a French national hospital database analysis. Benjamin L, Cotte FE, Mercier F, Vainchtock A, Vidal-Trecan G, Durand-Zaleski I, J Med Econ 2012 15 3 493 499 10.3111/13696998.2012.662924 22304337
28. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Pelletier EM, Shim B, Goodman S, Amonkar MM, Breast Cancer Res Treat 2008 108 2 297 305 10.1007/s10549-007-9601-0 17577662 (Pubitemid 351311367)
29. Amalric F, Analyse Economique des Coûts du Cancer en France Boulogne-Billancourt: Institut National du Cancer 2007